T W Weiss

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. pmc Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
    Beatriz Serrano
    Unit of Infections and Cancer UNIC, Cancer Epidemiology Research Program CERP, IDIBELL, Institut CatalĂ  d Oncologia ICO Catalan Institute of Oncology, Gran Via de L Hospitalet, 199 203, L Hospitalet de Llobregat, Barcelona, Spain
    Infect Agent Cancer 7:38. 2012
  2. pmc Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women
    Gregory D Zimet
    Department of Pediatrics, Indiana University School of Medicine, 410 W, 10th Street, HS 1001, Indianapolis, IN 46202, USA
    BMC Womens Health 10:27. 2010
  3. doi request reprint Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females
    Thomas W Weiss
    Global Health Outcomes, Merck and Co, Inc, 770 Sumneytown Pike, West Point, PA 19486 0004, USA
    J Adolesc Health 47:3-11. 2010
  4. ncbi request reprint Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills
    Thomas W Weiss
    US Outcomes Research, Merck and Co, Inc, West Point, PA 19486 0004, USA
    Curr Med Res Opin 23:2193-203. 2007
  5. pmc Osteoporosis medication profile preference: results from the PREFER-US study
    Thomas W Weiss
    Outcomes Research, Merck and Co, Inc, West Point, PA 19486, USA
    Health Expect 10:211-23. 2007
  6. ncbi request reprint Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study
    T W Weiss
    US Outcomes Research, Merck and Co Inc, PO Box 4 WP39 166, West Point, PA 19486, USA
    Osteoporos Int 18:1473-80. 2007
  7. ncbi request reprint An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study
    Thomas W Weiss
    Merck and Co, Inc, West Point, PA 19486, USA
    Curr Med Res Opin 22:949-60. 2006
  8. ncbi request reprint Care provided by VA mobile clinic staff during Northridge earthquake relief
    T Weiss
    Merck and Co, Inc, West Point, PA 19486 0004, USA
    Prehosp Disaster Med 14:191-7. 1999
  9. ncbi request reprint An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture
    Y T Chen
    Department of Outcomes Research and Management, Merck and Co, Inc, 770 Sumneytown Pike, West Point, PA 19486, USA
    Osteoporos Int 18:1287-96. 2007
  10. ncbi request reprint The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates
    Colleen A McHorney
    U S Outcomes Research, Merck and Co, Inc, West Point, PA 19486 0004, USA
    Curr Med Res Opin 23:3137-52. 2007

Collaborators

Detail Information

Publications13

  1. pmc Potential impact of a nine-valent vaccine in human papillomavirus related cervical disease
    Beatriz Serrano
    Unit of Infections and Cancer UNIC, Cancer Epidemiology Research Program CERP, IDIBELL, Institut CatalĂ  d Oncologia ICO Catalan Institute of Oncology, Gran Via de L Hospitalet, 199 203, L Hospitalet de Llobregat, Barcelona, Spain
    Infect Agent Cancer 7:38. 2012
    ..abstract:..
  2. pmc Reasons for non-vaccination against HPV and future vaccination intentions among 19-26 year-old women
    Gregory D Zimet
    Department of Pediatrics, Indiana University School of Medicine, 410 W, 10th Street, HS 1001, Indianapolis, IN 46202, USA
    BMC Womens Health 10:27. 2010
    ..The purpose of this study was to better understand reasons for non-vaccination among insured 19-26 year-old women and to evaluate future vaccination intentions...
  3. doi request reprint Human papillomavirus vaccination of males: attitudes and perceptions of physicians who vaccinate females
    Thomas W Weiss
    Global Health Outcomes, Merck and Co, Inc, 770 Sumneytown Pike, West Point, PA 19486 0004, USA
    J Adolesc Health 47:3-11. 2010
    ..We assessed U.S. physicians' attitudes and perceptions regarding potential human papillomavirus (HPV) vaccination of males...
  4. ncbi request reprint Persistence across weekly and monthly bisphosphonates: analysis of US retail pharmacy prescription refills
    Thomas W Weiss
    US Outcomes Research, Merck and Co, Inc, West Point, PA 19486 0004, USA
    Curr Med Res Opin 23:2193-203. 2007
    ..Determine whether monthly dosing of bisphosphonates has an impact on persistence relative to weekly dosing...
  5. pmc Osteoporosis medication profile preference: results from the PREFER-US study
    Thomas W Weiss
    Outcomes Research, Merck and Co, Inc, West Point, PA 19486, USA
    Health Expect 10:211-23. 2007
    ..To assess patient preferences for two osteoporosis medications...
  6. ncbi request reprint Osteoporosis practice patterns in 2006 among primary care physicians participating in the NORA study
    T W Weiss
    US Outcomes Research, Merck and Co Inc, PO Box 4 WP39 166, West Point, PA 19486, USA
    Osteoporos Int 18:1473-80. 2007
    ..These results suggest some significant improvements in osteoporosis management over the past eight years...
  7. ncbi request reprint An evaluation of patient preferences for osteoporosis medication attributes: results from the PREFER-US study
    Thomas W Weiss
    Merck and Co, Inc, West Point, PA 19486, USA
    Curr Med Res Opin 22:949-60. 2006
    ..To evaluate preferences for eight medication attributes that women may consider when evaluating prescription osteoporosis medications...
  8. ncbi request reprint Care provided by VA mobile clinic staff during Northridge earthquake relief
    T Weiss
    Merck and Co, Inc, West Point, PA 19486 0004, USA
    Prehosp Disaster Med 14:191-7. 1999
    ..From 25 January 1994 to 02 February 1994, staff aboard four Veterans Affairs Mobile Clinics treated Northridge earthquake victims. This study examined the types of conditions treated by Clinic staff during the disaster...
  9. ncbi request reprint An approach for identifying postmenopausal women age 50-64 years at increased short-term risk for osteoporotic fracture
    Y T Chen
    Department of Outcomes Research and Management, Merck and Co, Inc, 770 Sumneytown Pike, West Point, PA 19486, USA
    Osteoporos Int 18:1287-96. 2007
    ..These algorithms correctly identified postmenopausal women between the ages of 50 and 64 years who were at the highest risk of osteoporotic fracture within 36 months...
  10. ncbi request reprint The impact of osteoporosis medication beliefs and side-effect experiences on non-adherence to oral bisphosphonates
    Colleen A McHorney
    U S Outcomes Research, Merck and Co, Inc, West Point, PA 19486 0004, USA
    Curr Med Res Opin 23:3137-52. 2007
    ....
  11. ncbi request reprint Interactive voice response telephone calls to enhance bone mineral density testing
    Jennifer M Polinski
    Division of Pharmacoepidemiology and Pharmacoeconomics, 1620 Tremont St, Ste 3030, Boston, MA 02120, USA
    Am J Manag Care 12:321-5. 2006
    ..Bone mineral density (BMD) testing is a key tool used to diagnose and treat osteoporosis. We assessed the rate of scheduling BMD tests among health plan members at risk for osteoporosis who received interactive voice response (IVR) calls...
  12. pmc Improving osteoporosis screening: results from a randomized cluster trial
    Jennifer Elston Lafata
    Center for Health Services Research, Henry Ford Health System, Detroit, Michigan 48202, USA
    J Gen Intern Med 22:346-51. 2007
    ..We present results from a clustered, randomized trial evaluating patient mailed reminders, alone and in combination with physician prompts, to improve osteoporosis screening and treatment...
  13. pmc Cholesterol levels and statin use in patients with coronary heart disease treated in primary care settings
    PATRICK J O'CONNOR
    HealthPartners Research Foundation and HealthPartners Medical Group, PO Box 1524, Mail Stop 21111R, Minneapolis, MN 55440 1524, USA
    Prev Chronic Dis 2:A05. 2005
    ..The objective was to determine whether systems of care implemented within a large medical group are associated with improved treatment and control of dyslipidemia in a high-risk group of coronary heart disease patients...